Compounded tirzepatide vs Zepbound: cost, safety, and the rules

No. Zepbound is FDA-approved tirzepatide, manufactured to strict standards and studied in the large SURMOUNT trials. Compounded tirzepatide is mixed by a compounding pharmacy, is not FDA-approved, and was never put through the FDA efficacy or safety review — there are no trials of the compounded product. Its strength, purity, and consistency are not FDA-verified, some compounders have used salt-form variants the FDA has flagged, and the FDA has received hundreds of adverse-event reports tied to compounded tirzepatide.

Much less than before. Widespread compounding was permitted while tirzepatide was in FDA shortage, but that shortage was declared resolved in December 2024, and the enforcement grace periods for pharmacies ended in 2025 (503A in early 2025, 503B in March 2025). In 2026 the FDA proposed further restricting bulk tirzepatide compounding. So the flood of cheap compounded tirzepatide has largely receded. Compounding may still be legitimate in narrower, individualized situations, but that is different from mass-market copies — and a site still selling it freely is a reason for more caution, not less.

Compounded tirzepatide has been advertised around $99–$450/mo, versus Zepbound's list price of about $1,086/mo. But Zepbound's real self-pay cost is far below list through Lilly's cash program — around $299/mo (2.5 mg) at the starting dose and roughly $449/mo (7.5 mg and up) at maintenance if you refill on schedule. So the honest gap between the FDA-approved option and compounded is smaller than "list vs compounded" makes it look — compare the actual price you would pay.

The FDA has warned that some compounded GLP-1 products used salt forms of the active ingredient that differ from the approved base molecule, with unknown safety and efficacy. For tirzepatide, that means a compounded vial may not contain exactly the same active ingredient as Zepbound. If you are considering compounded tirzepatide, confirming that it is the base molecule — not a salt variant — is one of the most important safety checks you can make.

Zepbound is the only tirzepatide actually tested for safety and effectiveness, and with the cash program the price gap has narrowed — so start there if you can. If cost still points you to compounded, reduce the risk: use a provider dispensing through a reputable (ideally 503B) pharmacy, confirm it is base tirzepatide, insist on clear dosing instructions and pre-measured or clearly labeled syringes, and never buy without a prescription and a real clinician. This is a trade-off to weigh with a licensed professional, not a price-only decision.

Almost never — and that is where the price comparison often inverts. A compounded program's cash price is the whole price permanently: no copay to fall back on, no appeal route if it rises. Zepbound can drop to a copay if covered, a denial can be appealed, and Lilly's self-pay program is a further fallback. Find out what your plan would actually charge for Zepbound before deciding on headline cost alone.

Because compounded pricing is normally tiered by strength, and tirzepatide has more dose steps than semaglutide. A quote at the starting dose can be well below what you pay at a maintenance strength months later. Ask for the full price ladder — every strength, not just the first — before committing. This gap between the advertised number and the real ongoing cost is the single biggest reason people are surprised by their compounded bill.

Six things: which pharmacy dispenses it and where it is licensed; whether it is base tirzepatide, in writing; the dosing instructions in both units and milligrams, since unit confusion is a documented source of dosing errors in this category; the full price ladder across every dose strength; the refund policy if you stop, since discontinuation during titration is common; and who you contact clinically if something goes wrong — a named clinician, not a support inbox. Vague answers on dosing in particular are a reason to stop.